Evidence map›Paper›PMID 18465235›Full record

ArticleDigestive diseases and sciences2008

Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat.

Giuseppe Celasco, Luigi Moro, Roberta Bozzella, Katia Mangano, Cinzia Quattrocchi, Caterina Aiello, Marco Donia, Paolo Fagone, Roberto Di Marco

Erratum issuedOpen access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015
    Article
  5. Article
  6. Review
  7. Recent advances in the management of distal ulcerative colitis.World journal of gastrointestinal pharmacology and therapeutics · 2010
    Article
  8. Emerging drugs for the treatment of ulcerative colitis.Expert opinion on emerging drugs · 2009
    Review
  9. Review
  10. Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.American journal of physiology. Gastrointestinal and liver physiology · 2008
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Giuseppe CelascoCosmo Research and Development Srl, Via C. Colombo 1, 20020, Lainate, MI, Italy. giuseppe.celasco@cosmopharmaceuticals.com
Luigi Moro
Roberta Bozzella
Katia Mangano
Cinzia Quattrocchi
Caterina Aiello
Marco Donia
Paolo Fagone
Roberto Di Marco
University of Catania · ITCosmo Pharmaceuticals (Italy) · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeParenteral administration of low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH) resulted effective in improving the symptoms of experimental colitis in rat. Today, there is little information about their activity by intracolonic instillation. The scope of this study was to evaluate the ability of CB-01-05 (a LMWH with a mean molecular weight of about 5,700), compared to a series of other LMWHs and to UFH, directly instilled into the distal colon of the rat, to ameliorate dinitrobenzene (DNB)-induced experimental colitis.

methodAdult male Wistar rats underwent colitis induction by intracolonic instillation of DNB. Starting 24 h after colitis induction, CB-01-05 (0.005-0.9 mg), other LMWHs (0.3-0.6 mg), and UFH (0.6 mg) were instilled, by rectal route, into the distal colon once a day for three consecutive days. On the day following the last administration, the animals were sacrificed and the distal colon was isolated, weighed, macroscopically examined, and processed for histology. Additional experiments in rat splenocytes, performed in order to elucidate the anti-inflammatory mechanisms of CB-01-05, were performed.

resultsAmong the tested items, only CB-01-05 at doses ranging from 0.2 to 0.9 mg was significantly effective in reducing colon weight increase and in improving both the mucosal damaged area and the histological score. The other LMWHs resulted far less effective, showing decreasing activity closely related with the decrease of their molecular weight, thus demonstrating their biological nonequivalence. CB-01-05 resulted also more active than UFH. CB-01-05 was shown to interfere with cytokines production by rat splenocytes, mainly inhibiting interferon (IFN)-gamma expression.

conclusionsCB-01-05 instilled into the colon is well tolerated, has strong anti-inflammatory effect on DNB-induced colitis in rat, and is the most effective agent among other LMWHs and UFH. These results suggest that the anti-inflammatory activity of CB-01-05, together with its topical administration, could represent a new approach in the management of ulcerative colitis.

Indexed as

Administration, RectalAnimalsColitisDinitrobenzenesDisease Models, AnimalDose-Response Relationship, DrugFibrinolytic AgentsHeparin, Low-Molecular-WeightInterferon-gammaMaleRatsRats, WistarSpleenDinitrobenzenesFibrinolytic AgentsHeparin, Low-Molecular-WeightInterferon-gammaparnaparin

Identifiers

PMID18465235
OpenAlexW1998519641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.